MREOMereo BioPharma Group plc

MREO Stock Price, Valuation & Chart | Mereo BioPharma Group plc

Compare

$0.270-0.01 (-3.43%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology MREO intrinsic value MREO calculated fair value vs price

Overview Financials Dividends Ratios

MREO Historical price chart

MREO Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization42.65M

PE Ratio-5.34

EPS-0.05

Trading Volume804.85K

Today's High/Low0.28/0.26

Dividend Yield0.00

52 Week High/Low2.37/0.2

Shares Outstanding159.62M

MREO Financial Statement

MREO Analyst ratings

MREO Analysis & performance metrics

MREO Company profile

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and…

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also…

MREO Management team

Name

Position

Charles Edward Sermon

Co-Founder, General Counsel, Business Development & Company Secretary

Suba Krishnan

Senior Vice President of Clinical Development

Christine Fox CPACFO

Chief Financial Officer

Denise Vera Scots-Knight Ph.D.CEO

Co-Founder, Chief Executive Officer & Executive Director

Bo Kara

Senior Vice President and Head of Pharmaceutical Development & CMC

John P. Richard M.B.A.

Co-Founder & Chief Business Officer

John A. Lewicki Ph.D.

Chief Scientific Officer

Jackie Parkin

Senior Vice President & Therapeutic Head

Name

Position

Charles Edward Sermon

Co-Founder, General Counsel, Business Development & Company Secretary

Suba Krishnan

Senior Vice President of Clinical Development

Christine Fox CPACFO

Chief Financial Officer

Denise Vera Scots-Knight Ph.D.CEO

Co-Founder, Chief Executive Officer & Executive Director

Bo Kara

Senior Vice President and Head of Pharmaceutical Development & CMC

John P. Richard M.B.A.

Co-Founder & Chief Business Officer

John A. Lewicki Ph.D.

Chief Scientific Officer

Jackie Parkin

Senior Vice President & Therapeutic Head

Management Team

Charles Edward Sermon

Co-Founder, General Counsel, Business Development & Company Secretary

Suba Krishnan

Senior Vice President of Clinical Development

Christine Fox CPACFO

Chief Financial Officer

Denise Vera Scots-Knight Ph.D.CEO

Co-Founder, Chief Executive Officer & Executive Director

Bo Kara

Senior Vice President and Head of Pharmaceutical Development & CMC

John P. Richard M.B.A.

Co-Founder & Chief Business Officer

John A. Lewicki Ph.D.

Chief Scientific Officer

Jackie Parkin

Senior Vice President & Therapeutic Head

Management

Charles Edward Sermon

Co-Founder, General Counsel, Business Development & Company Secretary

Suba Krishnan

Senior Vice President of Clinical Development

Christine Fox CPACFO

Chief Financial Officer

Denise Vera Scots-Knight Ph.D.CEO

Co-Founder, Chief Executive Officer & Executive Director

Bo Kara

Senior Vice President and Head of Pharmaceutical Development & CMC

John P. Richard M.B.A.

Co-Founder & Chief Business Officer

John A. Lewicki Ph.D.

Chief Scientific Officer

Jackie Parkin

Senior Vice President & Therapeutic Head

Total 8 executives

MREO Frequently asked questions

What is Mereo BioPharma Group plc (MREO) Stock Price?

Current stock price of Mereo BioPharma Group plc (MREO) stock is $0.270. The stock price is -3.43% lower in the session. The intraday range can be seen from this page. Volume of Mereo BioPharma Group plc (MREO) stock is 804.85K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Mereo BioPharma Group plc (MREO) stock price going up or down today?

The stock price of Mereo BioPharma Group plc (MREO) can change with earnings, company news, and overall market sentiment. Mereo BioPharma Group plc operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Mereo BioPharma Group plc stock expensive at its current price?

Whether Mereo BioPharma Group plc looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for MREO on this page is -5.34. EPS on this page is -0.05. Compare those figures with peers and growth expectations before deciding if the current Mereo BioPharma Group plc price is justified.

How has the stock price of Mereo BioPharma Group plc (MREO) performed historically?

Historical performance for Mereo BioPharma Group plc (MREO) is shown on the price chart on this page. Review multi-period moves alongside volume to see how MREO reacted to past earnings and market events.

Should I buy Mereo BioPharma Group plc (MREO) stock, at this price?

Buying Mereo BioPharma Group plc (MREO) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.